Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.270
+0.005 (0.40%)
At close: Aug 7, 2026, 4:00 PM EDT
1.348
+0.078 (6.13%)
Pre-market: Aug 10, 2026, 7:13 AM EDT

Coherus Oncology Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
11.5742.1726.39257.24211.04326.55
Revenue Growth
91.19%59.81%-89.74%21.89%-35.37%-31.37%
Gross Profit
3.6128.3617.6698.25140.96268.96
Operating Income
-44.33-181.13-199.65-203.2-256.88-263.86
Net Income
-103.12519.17272.41-237.89-291.75-287.1
Earnings Per Share
-1.031.430.25-2.53-3.76-3.81
EPS Growth
-472.00%----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
105.31172.13125.99117.75191.68417.2
Total Debt
37.2538.51268.21478.7476.1415.53
Net Cash (Debt)
68.06133.62-142.23-360.95-284.421.66
Net Cash Growth
-65.69%-----98.69%
Net Cash Per Share
0.521.14-1.24-3.83-3.660.02

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-186.03-138.51-20.44-174.88-241.12-37.43
Capital Expenditures
------1.29
Free Cash Flow
-186.03-138.51-20.44-174.88-241.12-38.72
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
31.18%67.24%66.93%38.19%66.79%82.36%
Operating Margin
-383.14%-429.51%-756.58%-78.99%-121.72%-80.80%
Pretax Margin
-1392.67%-434.23%-816.23%-92.62%-138.24%-87.92%
Profit Margin
-1141.92%398.43%108.03%-92.48%-138.25%-87.92%
FCF Margin
-1607.73%-328.45%-77.46%-67.98%-114.25%-11.86%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-0.995.52---
Forward PE
-138.2923.3123.3123.3123.31
PS Ratio
3.854.086.051.452.923.76